Individual DD refers to the variety of biological characteristics of an organism that vary according to its genes. With the development of medical science, more and more attention has been paid to the relationship between human menstruation and individual diseases; the relationship between disease efficacy and individual diseases, thus revealing why the same disease in nature has different prognosis; why only some patients with chronic hepatitis B develop hepatitis cirrhosis and even hepatocellular liver cancer; why the same drug has different efficacy for different people and the family predisposition of tumors, immune diseases, etc. can now be explained by individual differences in each person. Why the same drug has different efficacy for different people, and the family tendency of tumor, immune disease, etc., can now be explained by the individual differences of each person. For example, in the same family, there is an old woman and her wife who suffer from hypertension and take the same drug, but the results are very different, the old man’s blood pressure is not well controlled and he has to switch to other drugs. Another example is that in patients with chronic hepatitis B, who have similar conditions and are of similar age, the same interferon is used for antiviral treatment for 6 months, but not all of them are effective, and the efficiency rate is only 40%; another example is that in patients with similar conditions who use lamivudine at the same time, some have resistance for 9 months, while others can use it for 2-3 years before resistance occurs. This phenomenon is the result of individual genetic differences. Recently, one of the hot topics of research by domestic and foreign scholars is the relationship between single nucleotide polymorphism analysis of human genes and the occurrence, development and regression of various diseases. Studies have shown that individuals with the CC genotype who are infected with HBV have a higher risk of developing chronic persistent infection than other genotypes. Of course this is related to individual differences, but also to the hepatitis virus genotype and the complete treatment regimen. We know that domestic and foreign hepatologists have reached a consensus on the treatment of hepatitis B and C. For patients with viral hepatitis, the first emphasis should be on antiviral therapy, followed by immunomodulatory, liver-protective and enzyme-lowering, and anti-fiber therapy. How can we improve the efficiency of hepatitis treatment is a common concern for our doctors and patients. I would like to introduce my clinical experience and related knowledge to you, please point out any inappropriate points: a. The development of a realistic and feasible treatment plan is the basis of successful treatment. 1.Which patients should be treated with antiviral therapy? Patients diagnosed with chronic hepatitis B, that is, either major or minor triplets, must be treated with antiviral therapy as long as their liver function is abnormal. However, it does not include hepatitis B virus carriers, liver cirrhosis, heavy hepatitis, etc. For a carrier of the virus to be regularly checked at the hospital, once found abnormal liver function timely antiviral treatment. Patients diagnosed with hepatitis C must be treated with antiviral therapy as long as the HCVRNA is positive, regardless of whether the liver function is normal or not. The earlier the antiviral treatment the better, hepatitis B virus infection to the human body 3 years after the beginning of integration into the nucleus of the liver cells, such as early treatment can reduce the chance of virus integration into the nucleus of the liver cells. 2. Carefully implement the treatment plan. For patients eligible for antiviral therapy, give antiviral therapy firmly and emphasize long-term treatment to reduce the reservoir of cccDNA and achieve the purpose of suppressing HBVDNA. During the treatment process, closely observe the changes in the disease and adjust the treatment plan in a timely manner. 3. For patients who have difficulty in achieving antiviral response, analyze the reasons, and also try combination therapy or sequential therapy, or add immunomodulators to the treatment. Second, understanding the genotype of the infected virus can predict the effect of antiviral therapy. The summary of domestic and international data shows that the distribution of viral genotypes is different in different regions. Our chronic hepatitis B viruses in Jiangsu and Anhui are mainly genotypes B and C. Numerous studies have shown that chronic hepatitis B patients with genotype B respond better to interferon than genotype C (response rate 39% vs. 17%); whereas lamivudine and adefovir are not related to genotype. Hepatitis C is mostly type 1 in China, and the response rate of type 1 to interferon is significantly lower than that of non-type 1. Third, interferon efficacy prediction of genetic testing (HepaType) is to predict the efficacy of individual to antiviral therapy. HepaType is a molecular testing tool to identify the genotype of patients with chronic hepatitis B. It can predict the responsiveness of patients with chronic hepatitis B to interferon treatment against chronic HBV or HCV virus infection. Performing this test prior to treatment can help physicians develop individualized antiviral treatment dosing regimens for their patients. Fourth, understanding one’s own cellular immune function can also be targeted for antiviral therapy. We all know that the clearance of hepatitis virus ultimately depends on our own immune function, especially the specific immune function. We can understand the autoimmune function by testing the cell subpopulation count. V. Emphasis on combination therapy. In addition to emphasizing antiviral therapy, the treatment of viral hepatitis must also properly understand the limitations of antiviral therapy and pay attention to the use of drugs to eliminate liver inflammation, anti-liver fiber drugs and immunomodulatory drugs in conjunction with antiviral therapy. In conclusion, there are no specific drugs available for the treatment of viral hepatitis. The current treatment must be based on the disease and take comprehensive treatment measures: for viral carriers, no treatment for the time being, dynamic regular follow-up, once the liver function abnormalities, formal treatment; for the onset of chronic hepatitis B patients, can take both the symptoms and the root cause of treatment, that is, antiviral treatment, control of inflammation, anti-liver fibrosis treatment; according to the individual, the development of individualized treatment plan in line with the patient himself.